GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (STU:94E) » Definitions » Inventories, Inventories Adjustments

Zura Bio (STU:94E) Inventories, Inventories Adjustments : €0.00 Mil (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Zura Bio Inventories, Inventories Adjustments?

Zura Bio's Inventories, Inventories Adjustments for the quarter that ended in Mar. 2025 was €0.00 Mil.


Zura Bio Inventories, Inventories Adjustments Historical Data

The historical data trend for Zura Bio's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zura Bio Inventories, Inventories Adjustments Chart

Zura Bio Annual Data
Trend Mar22 Dec23 Dec24
Inventories, Inventories Adjustments
- - -

Zura Bio Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Zura Bio Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


Zura Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zura Bio Ltd (STU:94E) » Definitions » Inventories, Inventories Adjustments
Traded in Other Exchanges
Address
1489 W. Warm Springs Road, Suite 110, Henderson, NV, USA, 89014
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.

Zura Bio Headlines

No Headlines